Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The US company also sells a small-molecule HER2 inhibitor – Tukysa (tucatinib) – which is now partnered with Merck & Co outside the US, Canada and Europe as part of a $4.2 billion alliance ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The recent approval of the dual-inhibitors (EGFR/HER2), such as lapatinib, opens a new avenue for therapeutic strategies with multitargeted drugs, not only directed against the surface receptors ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

In the SWOG S1613 clinical trial comparing this standard therapy to treatment with two HER2 inhibitors, these patients saw a similar level of clinical benefit, with lower toxicity, from the ...